Compare COE & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | LONA |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 81.5M |
| IPO Year | 2015 | 2020 |
| Metric | COE | LONA |
|---|---|---|
| Price | $20.00 | $7.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 13.6K | ★ 28.4K |
| Earning Date | 06-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.66 | $4.21 |
| 52 Week High | $56.13 | $14.21 |
| Indicator | COE | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 48.78 |
| Support Level | $15.16 | $6.86 |
| Resistance Level | $28.40 | $9.78 |
| Average True Range (ATR) | 1.17 | 0.47 |
| MACD | 0.40 | 0.08 |
| Stochastic Oscillator | 83.26 | 62.04 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.